Immune booster: donor NK cells aim to cut cancer recurrence

NCT ID NCT07247201

Not yet recruiting Disease control Sponsor: Singapore General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial tests whether adding natural killer (NK) cells from healthy donors to standard chemoradiotherapy can reduce the risk of cancer returning in people with advanced nasopharyngeal cancer. The study has two phases: first, finding the safest dose of NK cells, then testing that dose in more patients. Researchers will monitor side effects, blood markers, and recurrence rates over 2-3 years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: allogeneic natural killer (NK) cells from healthy donors
What this could lead to: If successful, this could point toward a new way to lower the chance of cancer coming back in people with advanced nasopharyngeal cancer.
What could go wrong: This is an early phase 1/2 trial with only 31 participants, so results may not apply to everyone. The NK cell therapy may not reduce recurrence or could cause unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MAXIMUM TOLERATED DOSE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

nasopharyngeal carcinoma Neoplasm, Residual

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MAXIMUM TOLERATED DOSE MINIMAL RESIDUAL DISEASE NASOPHARYNGEAL CARCINOMA (NPC) RECURRENT NASOPHARYNGEAL CARCINOMA

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Singapore General Hospital

Singapore, Singapore

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.